Curacyte GmbH is an advanced biopharmaceutical company dedicated to the development of new therapeutics for acute and critical care. After the sale of its preclinical technology platform for low molecular weight protease inhibitors to The Medicines Company, Curacyte has focussed all its efforts on the development of PHP / Hemoximer.

When the pivotal Phase III trial with PHP was terminated for futility, the company has also terminated its efforts in drug development.